Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Brian D. VanScoy"'
Autor:
Sujata M. Bhavnani, Jeffrey P. Hammel, Elizabeth A. Lakota, Michael Trang, Justin C. Bader, Catharine C. Bulik, Brian D. VanScoy, Christopher M. Rubino, Michael D. Huband, Lawrence Friedrich, Judith N. Steenbergen, Paul G. Ambrose
Publikováno v:
Antimicrobial Agents and Chemotherapy. 67
Omadacycline, a novel aminomethylcycline with in vitro activity against Gram-positive and -negative organisms, including Streptococcus pneumoniae and Haemophilus influenzae , is approved in the United States to treat patients with community-acquired
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f512cb865e5b1e50a1aff17b6dce35ce
https://doi.org/10.1128/aac.02213-21
https://doi.org/10.1128/aac.02213-21
Publikováno v:
Open Forum Infectious Diseases. 9
Background Tebipenem (TBP), an oral carbapenem in development for treatment of complicated urinary tract infections and acute pyelonephritis, is active vs. uropathogens which produce extended-spectrum beta-lactamases (ESBLs) such as Escherichia coli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ca6de60b8ba66714ae75713eee34484
https://doi.org/10.1093/ofid/ofac492.228
https://doi.org/10.1093/ofid/ofac492.228
Autor:
Brian D VanScoy, Haley Conde, Nicole Cotroneo, Ian A Critchley, Thomas R Parr, Paul G Ambrose
Publikováno v:
Open Forum Infectious Diseases
Background SPR994 is an orally bioavailable pivoxil hydrobromide prodrug of tebipenem, a novel oral carbapenem with activity against Gram-positive and -negative bacteria currently under development for the treatment of urinary tract infections (UTI).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2d01e17fb882efa5913f5e8692a70b2
http://europepmc.org/articles/PMC8644764
http://europepmc.org/articles/PMC8644764
Autor:
Jill Lindley, Timothy B Doyle, Brian D VanScoy, Christopher M Rubino, Sujata M Bhavnani, Paul G Ambrose, Mariana Castanheira
Publikováno v:
Open Forum Infectious Diseases. 8:S629-S631
Background Escherichia coli ST131 is a major challenge for global human health. Among ST131 isolates, the H30 type is prevalent and displays multiple drug resistance to classes. A monoclonal antibody (mAb) specific for the O antigen, O25b, which is c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99d3763d5df5ea40278d9f0c14c7c2ca
https://doi.org/10.1093/ofid/ofab466.1272
https://doi.org/10.1093/ofid/ofab466.1272
Autor:
Brian D, VanScoy, Nicole E, Scangarella-Oman, Steven, Fikes, Sharon, Min, Jianzhong, Huang, Karen, Ingraham, Sujata M, Bhavnani, Haley, Conde, Paul G, Ambrose
Publikováno v:
Antimicrobial agents and chemotherapy. 64(10)
Multidrug-resistant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7b06876418d6d63dcce3f720f6312b2d
https://pubmed.ncbi.nlm.nih.gov/32661002
https://pubmed.ncbi.nlm.nih.gov/32661002
Autor:
Brian D, VanScoy, Elizabeth A, Lakota, Haley, Conde, Jennifer, McCauley, Lawrence, Friedrich, Judith N, Steenbergen, Paul G, Ambrose, Sujata M, Bhavnani
Publikováno v:
Antimicrobial Agents and Chemotherapy
Omadacycline is a novel aminomethylcycline with activity against Gram-positive and -negative organisms, including Haemophilus influenzae, which is one of the leading causes of community-acquired bacterial pneumonia (CABP). The evaluation of antimicro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7e8786fc707ef8e605df2a491574fdd4
https://pubmed.ncbi.nlm.nih.gov/32284378
https://pubmed.ncbi.nlm.nih.gov/32284378